(OPCH) Option Care Health - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68404L2016
OPCH: Infusion, Therapies, Nutrition, Medications, Nursing, Services
Option Care Health, Inc. (NASDAQ:OPCH) is a leading provider of home and alternate-site infusion services in the United States. The company specializes in delivering complex therapies in non-hospital settings, reducing healthcare costs while improving patient outcomes. Their services span a wide range of clinical needs, including anti-infective therapies, heart failure treatments, parenteral and enteral nutrition, and immunoglobulin infusions for immune deficiencies. They also address chronic inflammatory conditions like Crohn’s disease, psoriasis, and rheumatoid arthritis, as well as neurological disorders such as multiple sclerosis and muscular dystrophy. Additionally, the company offers infusion therapies for bleeding disorders, high-risk pregnancies, pain management, chemotherapy, and respiratory conditions, complemented by nursing support.
Option Care Health operates through a referral-based model, working closely with physicians, hospital discharge planners, and health organizations to ensure seamless patient transitions to home-based care. This approach aligns with the broader healthcare industry’s shift toward cost-effective, patient-centric care delivery. Headquartered in Bannockburn, Illinois, the company is well-positioned to benefit from the growing demand for outpatient infusion services.
From a financial perspective, Option Care Health has a market capitalization of approximately $5.27 billion, reflecting its scale and market presence. The company trades at a P/E ratio of 25.82, with a forward P/E of 25.45, suggesting investor confidence in its growth prospects. Its price-to-book ratio of 3.70 indicates a premium valuation relative to its book value, while the price-to-sales ratio of 1.10 highlights its revenue generation capabilities. These metrics provide insight into the company’s financial health and its position as a key player in the healthcare services sector.
Additional Sources for OPCH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
OPCH Stock Overview
Market Cap in USD | 5,330m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1996-08-15 |
OPCH Stock Ratings
Growth 5y | 65.7% |
Fundamental | 46.3% |
Dividend | 0.0% |
Rel. Strength Industry | 1.8 |
Analysts | 3.9/5 |
Fair Price Momentum | 35.40 USD |
Fair Price DCF | 40.23 USD |
OPCH Dividends
No Dividends PaidOPCH Growth Ratios
Growth Correlation 3m | 95.6% |
Growth Correlation 12m | -9.1% |
Growth Correlation 5y | 74.6% |
CAGR 5y | 29.07% |
CAGR/Max DD 5y | 0.75 |
Sharpe Ratio 12m | 0.73 |
Alpha | -4.49 |
Beta | 0.46 |
Volatility | 31.71% |
Current Volume | 2194.2k |
Average Volume 20d | 1884.9k |
As of March 15, 2025, the stock is trading at USD 32.66 with a total of 2,194,208 shares traded.
Over the past week, the price has changed by -3.97%, over one month by +3.81%, over three months by +39.22% and over the past year by +2.70%.
Partly, yes. Based on ValueRay Fundamental Analyses, Option Care Health (NASDAQ:OPCH) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 46.26 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of OPCH as of March 2025 is 35.40. This means that OPCH is currently overvalued and has a potential downside of 8.39%.
Option Care Health has received a consensus analysts rating of 3.90. Therefor, it is recommend to buy OPCH.
- Strong Buy: 3
- Buy: 3
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, OPCH Option Care Health will be worth about 38.3 in March 2026. The stock is currently trading at 32.66. This means that the stock has a potential upside of +17.3%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 37.8 | 15.7% |
Analysts Target Price | 29.7 | -9.2% |
ValueRay Target Price | 38.3 | 17.3% |